ARTICLE | Company News
Piqur, Eisai deal
February 22, 2016 8:00 AM UTC
Piqur will conduct a Phase I/IIb trial combining breast cancer drug Halaven eribulin mesylate from Eisai with the biotech’s PQR309 to treat triple-negative breast cancer (TNBC). PQR309, a phosphoin...